AbbVie Inc. $ABBV Stock Sold by Searle & CO.

Posted by Geri Gentry on Nov 11th, 2026

Searle & CO. cut its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 45,202 shares of the company’s stock after selling 4,000 shares during the quarter. AbbVie makes up about 2.8% of Searle & CO.’s holdings, making the stock its 6th largest holding. Searle & CO.’s holdings in AbbVie were worth $11,824,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. State Street Corp grew its holdings in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of AbbVie during the 2nd quarter worth approximately $2,905,952,000. Deutsche Bank AG raised its holdings in shares of AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after acquiring an additional 1,241,587 shares in the last quarter. Finally, Amundi raised its holdings in shares of AbbVie by 2.4% during the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock worth $2,326,728,000 after acquiring an additional 247,689 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ABBV shares. Argus boosted their price target on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Sanford C. Bernstein reiterated a “market perform” rating and set a $275.00 price objective on shares of AbbVie in a research report on Monday, November 2nd. Oppenheimer lifted their price objective on shares of AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Finally, UBS Group boosted their target price on shares of AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $297.46.

Check Out Our Latest Stock Report on ABBV

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $293.88 on Wednesday. The firm has a market cap of $519.46 billion, a PE ratio of 50.58, a price-to-earnings-growth ratio of 1.33 and a beta of 0.20. The firm’s 50 day simple moving average is $273.45 and its 200-day simple moving average is $239.80. AbbVie Inc. has a one year low of $190.75 and a one year high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the prior year, the company earned $1.86 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that AbbVie Inc. will post 13.98 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is presently 125.30%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.